Philips and Elekta deepen strategic partnership in precise and individualized oncology care
07 Junio 2021 - 1:30AM
Philips and Elekta deepen strategic partnership in precise and
individualized oncology care
June 7, 2021Healthcare leaders partner to streamline the path
from cancer diagnosis to survivorship for better outcomes
Amsterdam, the Netherlands, and Stockholm,
Sweden – Royal Philips (NYSE: PHG, AEX:
PHIA), and Elekta (EKTA-B.ST) today signed agreements to deepen
their existing strategic partnership to advance comprehensive and
personalized cancer care through precision oncology solutions.
The extended collaboration builds on the two companies’
successful cooperation in the fast-emerging field of magnetic
resonance (MR)-guided adaptive radiation therapy. Through deeper
cross-portfolio collaboration, Philips and Elekta will utilize
their complementary capabilities to further improve patient
care.
Benefiting patients throughout the care
pathwayOncology care is transforming, driven by an
increasingly precise diagnosis of each tumor, and a continuously
expanding range of therapy options. To fully capitalize on these
opportunities, healthcare providers require integrated solutions
throughout the entire cancer care pathway, from diagnosis to
treatment and follow-up.
This integrated approach has the potential to provide:
- Quicker, more accurate visualization of the tumor
- Easier decision of optimal treatment strategy
- Earlier assessment of therapy response
- More effective and efficient therapy delivery
The strengthened strategic partnership intends to further
deliver a superior experience in diagnosis and adaptive,
personalized treatments for clinicians, shorter treatment times and
more precise therapy for patients, and lowered costs of care for
healthcare providers.
“To capitalize on the opportunities presented by increasingly
precise diagnosis and the fast-expanding range of therapies
available for cancer patients, it’s essential to provide integrated
systems and solutions that provide the right insights at the right
time throughout each patient’s care journey,” said Kees Wesdorp,
Chief Business Leader of Precision Diagnosis at Philips. “By
deepening our already-successful collaboration with Elekta, we will
accelerate towards our goal of providing clear care pathways and
predictable outcomes for every cancer patient. Today’s announcement
is an important next step in the implementation of our strategy in
precision diagnosis.”
“I expect this extended partnership to unlock opportunities that
will provide better outcomes for people with cancer,” said Gustaf
Salford, Elekta’s President and CEO. “Together, we’ll combine
advanced informatics and image-guided radiation therapy solutions
to deliver greater precision in oncology. This means easier
selection by clinicians of the optimal treatment strategy and more
efficient and effective therapy delivery.”
In this preferred, although non-exclusive, partnership, Elekta
and Philips will leverage their capabilities to pursue integrated
vendor-agnostic solutions, enhancing interoperability between the
two parties’ systems and software in order to drive precision in
oncology.
For further information, please contact:
Mark GrovesPhilips Global Press OfficeTel: +31 631 639
916E-mail: mark.groves@philips.com
Mattias ThorssonVice President, Head of Corporate
Communications, ElektaTel: +46 70 865 8012E-mail:
mattias.thorsson@elekta.com
Cecilia KetelsHead of Investor Relations, ElektaTel: +46 76 611
76 25E-mail: cecilia.ketels@elekta.com
About Royal PhilipsRoyal Philips (NYSE: PHG,
AEX: PHIA) is a leading health technology company focused on
improving people's health and well-being, and enabling better
outcomes across the health continuum – from healthy living and
prevention, to diagnosis, treatment and home care. Philips
leverages advanced technology and deep clinical and consumer
insights to deliver integrated solutions. Headquartered in the
Netherlands, the company is a leader in diagnostic imaging,
image-guided therapy, patient monitoring and health informatics, as
well as in consumer health and home care. Philips generated 2020
sales of EUR 17.3 billion and employs approximately 77,000
employees with sales and services in more than 100 countries. News
about Philips can be found at www.philips.com/newscenter.
About ElektaFor almost five decades, Elekta has
been a leader in precision radiation medicine. Our more than 4,000
employees worldwide are committed to ensuring everyone in the world
with cancer has access to – and benefits from – more precise,
personalized radiotherapy treatments. Headquartered in Stockholm,
Sweden, Elekta is listed on NASDAQ Stockholm Exchange.
Visit elekta.com or follow @Elekta on Twitter.
Koninklijke Philips NV (EU:PHIA)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Koninklijke Philips NV (EU:PHIA)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024